Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Eisenmenger Patients
NCT00586794Phase 3Terminated
- Sponsor
- Competence Network for Congenital Heart Defects
- Start
- Dec 2007
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Eisenmenger syndrome comparing Sildenafil with Placebo (2 arms). Primary endpoints: 6-Minute Walk Distance at 26 weeks, Oxygen Saturation at 26 weeks and 1 more. Started Dec 2007; status: terminated.
02
Drugs
sildenafil
03
Conditions
Eisenmenger syndrome
Beyond the preview
Go deeper on NCT00586794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00586794.